United Therapeutics Corp logo

United Therapeutics Corp

3
3
NAS:UTHR (USA)   Ordinary Shares
$ 240.12 +5.65 (+2.41%) 12:14 PM EST
12.10
P/B:
1.89
Market Cap:
$ 11.30B
Enterprise V:
$ 8.78B
Volume:
165.28K
Avg Vol (2M):
512.12K
Also Trade In:
Volume:
165.28K
Avg Vol (2M):
512.12K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for UTHR ( United Therapeutics Corp ) from 1999 to Apr 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. United Therapeutics stock (UTHR) PE ratio as of Apr 24 2024 is 12.1. More Details

United Therapeutics Corp (UTHR) PE Ratio (TTM) Chart

To

United Therapeutics Corp (UTHR) PE Ratio (TTM) Historical Data

Total 1214
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
United Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-24 12.1 2024-02-20 10.8
2024-04-23 11.8 2024-02-16 10.8
2024-04-22 11.8 2024-02-15 10.8
2024-04-19 12.0 2024-02-14 10.8
2024-04-18 11.9 2024-02-13 10.8
2024-04-17 11.9 2024-02-12 10.9
2024-04-16 11.7 2024-02-09 10.7
2024-04-15 11.8 2024-02-08 10.7
2024-04-12 11.7 2024-02-07 10.6
2024-04-11 12.0 2024-02-06 10.8
2024-04-10 12.0 2024-02-05 10.7
2024-04-09 11.9 2024-02-02 10.8
2024-04-08 11.9 2024-02-01 10.9
2024-04-05 11.8 2024-01-31 10.8
2024-04-04 11.8 2024-01-30 10.8
2024-04-03 11.7 2024-01-29 10.9
2024-04-02 11.5 2024-01-26 11.0
2024-04-01 11.5 2024-01-25 11.1
2024-03-28 11.6 2024-01-24 11.0
2024-03-27 12.3 2024-01-23 11.0
2024-03-26 12.5 2024-01-22 10.9
2024-03-25 12.3 2024-01-19 11.0
2024-03-22 12.0 2024-01-18 11.0
2024-03-21 11.9 2024-01-17 11.2
2024-03-20 11.9 2024-01-16 11.0
2024-03-19 12.1 2024-01-12 11.0
2024-03-18 11.8 2024-01-11 11.1
2024-03-15 11.9 2024-01-10 11.2
2024-03-14 12.0 2024-01-09 11.3
2024-03-13 12.2 2024-01-08 11.7
2024-03-12 12.4 2024-01-05 11.6
2024-03-11 12.6 2024-01-04 11.6
2024-03-08 12.3 2024-01-03 11.5
2024-03-07 12.1 2024-01-02 11.5
2024-03-06 11.9 2023-12-29 11.1
2024-03-05 11.6 2023-12-28 11.1
2024-03-04 11.5 2023-12-27 11.8
2024-03-01 11.7 2023-12-26 11.9
2024-02-29 11.4 2023-12-22 12.1
2024-02-28 11.5 2023-12-21 12.0
2024-02-27 11.4 2023-12-20 12.4
2024-02-26 11.3 2023-12-19 13.2
2024-02-23 11.4 2023-12-18 13.6
2024-02-22 11.0 2023-12-15 13.6
2024-02-21 11.1 2023-12-14 14.0

United Therapeutics Corp (UTHR) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

United Therapeutics Corp logo
United Therapeutics Corp
NAICS : 325412 SIC : 2834
ISIN : US91307C1027

Share Class Description:

UTHR: Ordinary Shares
Description
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.